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Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths worldwide. These
tumors are commonly diagnosed at advanced stages and mortality rates remain high. Even cured patients suffer
the consequences of aggressive treatment that includes surgery, chemotherapy, and radiotherapy. In the past, in
clinical trials, HNSCC was considered as a single disease entity. Advances in molecular biology with the development
of genomic and proteomic approaches have demonstrated distinct prognostic HNSCC patient subsets beyond those
defined by traditional clinical–pathological factors such as tumor subsite and stage [Cho W (ed). An Omics Perspective
on Cancer Research. New York/Berlin: Springer 2010]. Validation of these biomarkers in large prospective clinical trials
is required before their clinical implementation. To promote this research, the European Organisation for Research and
Treatment of Cancer (EORTC) Head and Neck Cancer Program will develop the following strategies—(i) biobanking:
prospective tissue collection from uniformly treated patients in the setting of clinical trials; (ii) a group of physicians,
physician—scientists, and EORTC Headquarters staff devoted to patient-oriented head and neck cancer research;
(iii) a collaboration between the basic scientists of the Translational Research Division interested in head and neck
cancer research and the physicians of the Head and Neck Cancer Group; and (iv) funding through the EORTC Grant
Program and the Network Core Institutions Consortium. In the present report, we summarize our strategic plans to
promote head and neck cancer research within the EORTC framework.
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introduction
In 2002, the crude incidence rates of carcinoma of the head and
neck in Europe were 36/100 000/year in the male population
and 7/100 000/year for women, whereas the corresponding
mortality rates were 18 and 3/100 000/year. On the Europe
scale, head and neck cancer accounts for 139 000 new cases per
year. More than 90% of head and neck malignancies are
squamous cell carcinomas [1]. In Europe, the relative survival
rate for head and neck cancer patients was 72% at 1 year and
42% at 5 years in adults [2]. Five-year survival was higher in
women (51%) than in men (39%). The effect of age on survival
is marked. Survival at 5 years was 54% for the youngest age-
group (15–45 years) and 35% in the oldest group of patients
(‡75 years) [2].
Head and neck squamous cell carcinomas (HNSCCs)
represent a heterogeneous group of tumors in terms of the
etiology, biology, and clinical behavior. In the past, clinical
trials considered HNSCC as a single disease entity [3]. Genomic
and proteomic approaches and molecular epidemiology studies
have demonstrated that there is considerable heterogeneity
among HNSCCs beyond that defined by traditional clinical–
pathological factors [4, 5]. For example, the association of
human papillomavirus (HPV) with a subset of oropharyngeal
cancers (OPCs) elucidates how diversity in etiology affects
tumor biology and clinical behavior. Tobacco and alcohol use
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account for the vast majority of HNSCCs. Recently, high-risk
HPVs, especially type 16, have been implicated in the
pathogenesis of a subset of HNSCC, especially those arising
from the tonsillar oropharynx. Patients with HPV-positive
tumors are estimated to have a 50%–80% reduction in risk
of disease failure when compared with the HPV-negative
patients [5–7]. HPV-positive HNSCCs are characterized by p16
positivity [4] and relatively fewer genomic abnormalities. From
this point of view, HPV status should at least be included as
a stratification factor into future randomized, controlled trials
(RCT) and, in addition, it could be argued that separate RCTs
are needed for HPV-associated HNSCCs. Phase II/III clinical
trials that represent attempts to reduce toxicity burden with
minimal risk for inferior tumor control in patients with HPV-
positive HNSCCs are planned. A National Cancer Institute-
sponsored State of the Science Meeting on Head and Neck
Cancer and the HPV was convened on 9–10 November 2008 in
Washington, DC [8]. In this meeting, the principles of trial
design for HPV-positive patients were identified. A phase III
non-inferiority trial was not considered feasible due to the large
number of patients required. There was a near consensus that
a large randomized phase II trial design with a standard
control arm would be the most practical way to proceed.
Therefore, it has now become clear that future clinical trials
should take into account the molecular and clinical
heterogeneity of the disease and include important biomarkers
as stratification factors or predictive variables. This approach
may spare good-prognosis patients the side-effects of
unnecessary overtreatment suited for poor-prognostic subsets
that will benefit more from a more aggressive approach.
The European Organisation for Research and Treatment
of Cancer (EORTC) Head and Neck Cancer Group (HNCG)
has offered major contributions in the field of combined
modality approaches in locally advanced disease [9–13]. These
include (i) organ preservation programs in patients with
operable tumors, comparing immediate surgery versus
intended nonsurgical approaches (i.e. induction chemotherapy
followed by radiation in good responders) or comparing the
sequential approach (induction chemotherapy followed by
radiation in good responders) versus the alternating approach
(i.e. alternating chemotherapy and radiotherapy (RT) from the
start in all patients); (ii) postoperative management of locally
advanced tumors, comparing radiochemotherapy versus RT
alone; and (iii) induction chemotherapy programs in locally
advanced inoperable disease, comparing docetaxel
(Taxotere), cisplatin, and 5-fluorouracil (TPF) versus
cisplatin and 5-fluorouracil (PF) induction regimens. Despite
these advances, >50% of patients with locally advanced disease
die of cancer. In addition, the majority of surviving patients
suffer acute and late-treatment-related side-effects, mainly
salivary dysfunction and speech and swallowing impairment.
Advances in molecular biology have provided the tools to be
used for more accurate prognostic patient classification, early
detection, and toxicity prediction. Several prognostic and
predictive biomarkers have been identified using genomic and
proteomic approaches. The clinical application of these
biomarkers for early detection, outcome, and toxicity
prediction will improve survival and quality of life of patients
with HNSCC. However, validation of these biomarkers in large
prospective clinical trials is required before their clinical
implementation. The EORTC-HNCG has developed strategies
to promote patient-oriented laboratory research. This strategy
article will summarize ongoing and planned clinical trials,
outline planned translational research (TR) projects, and
describe strategies to promote translational head and neck
cancer research within the EORTC framework.
clinical trials in the EORTC-HNCG
Comprehensive information on ongoing clinical EORTC
trials can be found at the EORTC Web site (www.eortc.be).
locally advanced setting
EORTC 24971/TAX323 phase III clinical trial was an RCT
where patients with locally advanced (stages III and IV)
HNSCC were randomized to receive either PF induction
chemotherapy or TPF (docetaxel, cisplatin day 1, 5-fluorouracil
continuous infusion days 1–5) [13] every 3 weeks for four
cycles followed by RT alone. The results of this study revealed
that locoregional control, as well as overall survival (OS),
significantly improved with the TPF induction chemotherapy
regimen, while quality of life was maintained and was even
better in the TPF arm [13]. Based on the results of this
important trial, TPF has now become the standard when
chemotherapy is given for induction in patients with locally
advanced HNSCC. The EORTC-HNCG plans to correlate
tumor HPV DNA and p16 protein status with therapeutic
response and survival. In addition, functional p53 status and
b-tubulin expression status will be correlated with response
to docetaxel to see whether these biomarkers have the potential
to be used both as prognostic and as predictive factors.
Current clinical trials in HNSCC that combine chemotherapy
with targeted agents provide unique opportunities to test
hypothesis-driven TR questions. The ongoing EORTC 24061
study is a randomized phase II study in which cetuximab
[chimeric immunoglobulin G1 monoclonal antibody targeting
the epidermal growth factor receptor (EFGR)] is combined
with TPF for induction. After this induction biochemotherapy
regimen, patients with inoperable locally advanced HNSCC
will be randomly assigned to receive cisplatin-based or
carboplatin-based chemoradiation. A translational component
of this study will correlate clinical outcomes with EGFR
activation as determined by protein expression of EGFR and
downstream signaling molecules in tumor biopsies taken at
baseline. In addition, EGFR expression and downstream
signaling will also be evaluated in the reacting skin and matched
normal skin, in case of skin toxicity, with a comparison of data
from patients who have not shown skin toxicity. For these
translational studies, both tumor and skin biopsies are being
collected.
postoperative setting
EORTC protocol no. 22071-24071, an intergroup study of the
EORTC Radiation Oncology Group (ROG) and the EORTC-
HNCG, which will be activated in 2010, is a multicenter phase
III trial. A total of 800 patients with locoregionally advanced
HNSCCs primarily treated with surgery and showing high-risk
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features in the pathology specimen (i.e. positive or close
surgical margins and/or extranodal spread) will be randomly
assigned to receive postoperative cisplatin-based
chemoradiation (current standard) or the same postoperative
chemoradiation combined with panitumumab (a fully human
immunoglobulin G2 monoclonal antibody targeting the
EGFR). This study will include a number of TR projects. First,
both paraffin-embedded and frozen tumor material, as well as
blood and serum samples, will be collected and stored in
a central biobank. This collected material can be used in the
future for additional TR projects. Secondly, HPV DNA status
and protein expression of biomarkers representing key
molecules of the EGFR signaling pathway will be correlated
with response to panitumumab in the entire patient
population. Thirdly, the value of two predictive assays for
treatment-related toxicity will be tested including individual
intrinsic radiosensitivity by radiation-induced lymphocyte
apoptosis, and the identification of single nucleotide
polymorphisms (SNPs) associated with the development of
normal tissue toxicities, to see whether these assays would
(i) allow for identification of patients at risk for these side-
effects, (ii) allow for subsequent selection of patients that are
suitable candidates for preventive measures, and (iii) provide
essential information for RT treatment optimization. Fourthly,
150 patients will be enrolled before surgery (in a so-called
window study). In this pre-study cohort, gene expression
signatures before and after the administration of
a single panitumumab test dose will be correlated with
2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission
tomography (PET) response.
research areas of the HNCG
Translational Research Subcommittee
human papillomavirus
In addition to cervical cancer, the most widely acknowledged
HPV-associated malignancy, HPVs, especially type 16, are
implicated in the development of a subset of OPCs, particularly
in individuals that lack the traditional risk factors of tobacco
and alcohol abuse and mainly restricted to tonsillar OPCs.
Surveillance, Epidemiology, and End Results data have
demonstrated a rise in the annual incidence of base-of-tongue
and tonsil cancers by 2.1% and 3.9%, respectively, from 1973 to
2001 among white individuals aged 20–44 years, whereas the
incidence at other sites declined [14, 15] An increased incidence
of sexual behaviors associated with viral transmission through
this period, as shown by the increase in herpes simplex virus 2
seroprevalence over this time period, has been implicated for this
change in demographics. Licitra et al. [16] reported on the
incidence and survival outcomes of HPV-related and HPV-
unrelated HNSCC sites from 15 European (Sweden, Austria,
Slovenia, Scotland, Wales, Poland, Germany, the Netherlands,
Switzerland, Italy) population-based cancer registries including
29 265 adult patients with cancer diagnosed in the period from
1988 to 2002. Incidence rates of HNSCCs increased more for
HPV-related than HPV-unrelated cancer subsites. Three-year
survival rates improved more in HPV-related than in HPV-
unrelated cancer anatomic subsites. Along with epidemiological
evidence, experimental evidence also supports a causal role of
HPV in a subset of head and neck cancers. Rampias et al. [17]
showed that repression of HPV E6 and E7 oncogene expression
leads to apoptosis and restoration of p53 and pRb tumor
suppressor pathways in oropharyngeal squamous carcinoma cells.
HPV-associated HNSCCs are associated with better
prognosis compared with stage-matched HPV-negative ones in
the majority of studies [5, 6, 18–23]. HPV positivity confers
a 60%–80% reduction in risk of death from cancer relative to
similarly treated HPV-negative tumors. Licitra et al. [18] found
in a retrospective series of 90 patients with OPC treated
primarily with surgery that HPV-positive status significantly
affects OS (P = 0.0018), incidence of tumor relapse
(P = 0.0371), and second primary tumors (P = 0.0152). It has
also been shown that organ preservation strategies may be more
successful in HPV-associated OPCs compared with HPV-
negative ones [24]. It is important to emphasize, however, that
at present the contribution of the different therapeutic choices
to the survival benefit observed for the HPV-positive patient
remains unclear. In fact, literature data indicate that when
HPV-positive patients are treated similarly to age- and stage-
matched HPV-negative patients, the survival benefit observed is
independent of the type of therapy administered. Therefore,
patients with HPV-positive tumors may unnecessarily receive
treatments that significantly increase morbidity. Treatment
deintensification in the HPV-positive subgroup remains an
important research question. Clinical trials that stratify to more
or less intense therapy based on HPV status are only now being
undertaken.
Weinberger et al. [5] identified p16 protein expression by
immunohistochemistry (IHC) as a surrogate marker for
biologically and clinically relevant HPV infection. HPV DNA
detection by itself in HNSCC does not prove a causal
association. Only transcriptionally active HPV DNA is
biologically and clinically relevant in the causation of HNSCC.
They sought to determine the incidence and clinical
implications of biologically relevant HPV16 infection in
a cohort of 107 patients with oropharyngeal squamous cell
cancers treated primarily with RT or surgery followed by
postoperative RT at Yale University [5]. HPV16 DNA viral load
was determined by real-time PCR. In addition, they
constructed a tissue array composed of these tumors and
studied expression of p53, pRb, and p16 proteins using
a quantitative in situ method of protein analysis [automated
quantitative analysis (AQUA)]. They hypothesized that among
HPV16-DNA-positive cases, p16 expression status would
determine the biologically relevant ones. Their results
delineated three tumor classes with distinct molecular and
clinical features based on HPV16 DNA presence and p16
expression status: HPV16 negative/p16 nonexpressing (class I),
HPV16 positive/p16 nonexpressing (class II), and HPV16
positive/p16 expressing (class III) oropharyngeal tumors. OS in
class III was 79% compared with the other two classes (20%
and 18%, P = 0.0095). Disease-free survival rates for the same
classes were 75% versus 15% and 13% (P = 0.0025),
respectively. The 5-year local recurrence was 14% in class III
versus 45% and 74% in the other two classes (P = 0.03). Only
patients in class III had significantly lower p53 and pRb
expression (P = 0.017 and 0.001, respectively). Multivariate
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survival analysis confirmed the prognostic value of
the three-class model. They demonstrated that only the
HPV16-positive/p16-expressing tumors fit the cervical
carcinogenesis model and these are the ones associated with
a more favorable prognosis.
These findings were confirmed in two large prospective
studies [25, 26]. In the first study, patients with previously
untreated stage III or IV head and neck squamous cell cancer
were randomized to receive definitive RT concurrently with
either cisplatin or cisplatin plus tirapazamine. Slides were
available for HPV assay [in situ hybridization (ISH) HPV16/18]
in 195 patients and for p16 in 186 patients, and for both in 173
patients. Fifty-four of 195 (28%) tumors were HPV positive,
107 of 186 (58%) p16 positive. HPV-positive tumors were
associated with a better 2-year OS (94 versus 77%, P = 0.007)
and a better failure-free survival (FFS; 86 versus 75%,
P = 0.035) compared with HPV-negative tumors. Similarly,
p16-positive tumors were associated with a better 2-year OS (92
versus 75%, P = 0.004) and FFS (87 versus 72%, P = 0.003)
compared with the p16-negative ones. The second study was
conducted by Radiation Therapy Oncology Group in the USA
[26]. A correlative study was carried out to evaluate the
association of tumor HPV status (THS) and survival in
a randomized phase III trial comparing standard fractionation
(FX) RT and cisplatin (100 mg/m2, days 1, 22, and 43) with
accelerated FX-RT and cisplatin (100 mg/m2, days 1 and 22).
THS for OPC was determined by HPV16 ISH. THS was
evaluable for 73% (317 of 433) of OPC cases and 60.6% (55.2–
65.9) were HPV16 positive. OS or progression-free survival
(PFS) outcomes were similar for cases with and without HPV
determination. After median follow-up of 4.4 years, cases with
HPV-positive OPC had a better OS [P < 0.0001; 2-year 87.5%
(82.8–92.2) versus 67.2% (58.9–75.4)] and PFS [P < 0.0001;
2-year 71.9% (65.5–78.2) versus 51.2% (42.4–59.9)]. Patients
with HPV-positive OPC had a 59% reduction in risk of death
[hazard ratio (HR) 0.41 (0.27–0.64)] and a 46% reduction in
risk of progression or death [HR 0.54 (0.37–0.78)]. Ninety-six
percent of HPV-positive tumors were p16 positive. p16 status
was the most important prognosticator of outcome. p16
positivity conferred a 65% reduction in the risk of death,
whereas HPV positivity conferred a 55% reduction in the risk
of death. These results may be explained by the presence of
other HPV subtypes that were not assessed in the study.
Contrary to the findings of Sant et al. [2], in these two later
studies most of the HPV-positive cases were p16 positive.
This can be explained by the fact that HPV ISH, by detecting
integrated HPV DNA, is a more specific assay than real-
time PCR.
Smeets et al. [27] developed a detection algorithm for
a biologically and a clinically meaningful HPV infection. The
authors considered HPV E6 oncogene expression in frozen
biopsies as a gold standard for biologically meaningful HPV
infection and they tested the value of the following assays on
formalin-fixed, paraffin-embedded (FFPE) tumor specimens
and sera of 48 patients with HNSCC: HPV DNA general primer
(GP) 5+/6+ PCR, viral load analysis, HPV16 DNA FISH
detection, HPV16 E6 messenger RNA (mRNA) RT-PCR, and
p16 immunostaining, and on corresponding serum sample
detection of antibodies against the HPV16 proteins L1, E6, and
E7. Most suitable algorithm with 100% sensitivity and
specificity appeared p16 immunostaining, followed by GP5+/6+
PCR on the p16-positive cases. Taken together, the
incorporation of p16 IHC to the existing protocols for
determination of HPV DNA presence may distinguish the
transcriptionally active HPV-positive OPC.
To summarize, the current evidence supports the
conclusion that THS is an important and independent
prognostic factor for OS and disease-specific survival for
HNSCC. p16 protein status is also an important and
independent predictor of OS and disease-specific survival for
HNSCC. Future study design and data analysis should
acknowledge the unique natural history and prognosis of this
patient subgroup and incorporate HPV DNA and p16
protein status into the next generation of clinical trials. The
EORTC-HNCG plans to retrospectively evaluate the TAX323
study cohort for tumor HPV and p16 status in association
with treatment outcome per study arm. This retrospective
analysis will provide us with important information that will
be validated in the setting of a prospective three-arm trial
(first arm: TPF followed by anti-EGFR + RT versus second
arm: cisplatin + RT versus third arm anti-EGFR + RT)
planned by the EORTC-HNCG. This analysis will
demonstrate whether the addition of docetaxel to PF provides
additional benefit in the HPV+/p16+ patient subgroup. The
EORTC 22071-24071 postoperative study will also undergo
prospective HPV/p16 determination to demonstrate whether
HPV+/p16+ patients at high risk for recurrence derive
additional survival gain with the incorporation of
panitumumab to standard postoperative cisplatin-containing
chemoradiotherapy regimens.
signaling through the EGFR
The EGFR is a member of a receptor family known as the type I
receptor tyrosine kinases or ErbB receptors. This receptor
family includes the following four related receptors: EGFR
(ErbB1/EGFR/HER1), ErbB2 (HER2/neu), ErbB3 (HER3), and
ErbB4 (HER4). EGFR is a 170-kDa plasma membrane
glycoprotein that consists of an extracellular ligand-binding
domain, a hydrophobic transmembrane domain, and an
intracellular protein kinase domain with a regulatory COOH
terminal segment [28]. Ligand binding promotes receptor
dimerization leading to high-affinity ligand binding, activation
of the intrinsic protein kinase activity, and tyrosine
autophosphorylation. These events activate a signal
transduction cascade that is mitogenic and transforming.
Several lines of evidence support the conclusion that EGFR is
a molecular target for therapy of HNSCC. First, overexpression
of EGFR is one of the most frequent molecular alterations in
HNSCC [29]. The level of EGFR expression in HNSCC is
elevated compared with its expression on normal adjacent
squamous mucosa in 83%–100% of cases. Secondly, increased
EGFR content is often correlated with an increased production
of ligands, such as transforming growth factor alpha, by the
HNSCC [29]. Furthermore, treatment with EGFR-targeted
therapy such cetuximab (Erbitux) inhibits EGFR signaling and
sensitizes cancer cells to chemotherapy or radiation [30–32]. In
an international randomized phase III trial in patients with
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inoperable locally advanced disease, the addition of cetuximab
to radiotherapy prolonged time to locoregional recurrence and
survival compared with radiotherapy alone [30]. The overall
toxicity profile was dominated by traditional known effects
of curative head and neck radiation dose, although some
additional, mainly skin, toxicity was attributed to cetuximab.
In the recurrent/metastatic setting, a European randomized
phase III trial (EXTREME study) examined the addition of
cetuximab until disease progression in patients receiving six
cycles of cisplatin or carboplatin/5-fluorouracil chemotherapy
regimen as first-line treatment in recurrent or metastatic
HNSCC and showed a significantly improved survival in
cetuximab-treated patients [31]. Cetuximab alone is an
acceptable second-line therapy in recurrent or metastatic
HNSCC [33]. Taken together, abrogation of EGFR signaling
appears to be an effective therapeutic strategy in HNSCC.
A fundamental question in EGFR-targeted therapy has been
patient selection since the intensity of EGFR staining by IHC
has not been closely associated with the response rate and other
outcome measures. Studies evaluating EGFR expression in
tumor tissues are limited by the technical difficulties inherent in
assessing EGFR conventionally such as variability in
immunohistochemical techniques, different methods of
pathologist-based scoring, and the semiquantitative nature of
the assay. To overcome this problem, a method of in situ
AQUA has been developed, which allows measurements of
protein expression within subcellular compartments that results
in a number directly proportional to the number of molecules
expressed per unit area. Thus, we avoid biases introduced
from the arbitrary cut-off points used in conventional IHC.
Psyrri et al. [34] analyzed a cohort of 95 patients with OPC on
a tissue microarray for EGFR protein expression levels using
AQUA and correlated those with clinical and pathological data.
High nuclear and tumor EGFR protein levels were associated
with significantly higher local recurrence rates and inferior
disease-free survival and OS times. The finding that nuclear
EGFR is also a significant prognostic indicator is consistent
with data supporting nuclear localization and action of EGFR.
Lin et al. [35] showed that EGFR may enter directly the nucleus
and function as a transcription factor bypassing protein
phosphorylation cascades. EGFR AQUA score may prove
useful in predicting response to EGFR-targeted therapies.
Assessment of EGFR gene copy number has been associated
with response to EGFR-targeted therapies in other tumors.
Chung et al. [36] reported that increased EGFR gene copy
number by gene amplification or high polysomy using FISH
was a frequent genetic alteration in a cohort of patients with
HNSCC and was strongly associated with worse recurrence-free
survival and OS. FISH analysis of specimens from the
EXTREME study for EGFR gene amplification or polysomy
failed to show an association between FISH positivity and
outcomes in cetuximab-treated patients [37, 38].
Mechanisms of resistance to EGFR-targeted therapies have
extensively been studied in other tumor types. In lung cancer
for instance, catalytic domain EGFR mutations predict for
sensitivity to small-molecule tyrosine kinase inhibitors. In
colon cancer, KRAS and BRAF mutations predict for resistance
to cetuximab. These mutations are rare in patients with head
and neck cancer. At this point, the mechanisms of resistance
to EGFR-targeted therapies in patients with head and neck
cancer are largely unknown. Potential mechanisms of resistance
include the following: (i) constitutive up-regulation of
downstream targets of EGFR (i.e. the downstream target is no
longer regulated by EGFR), (ii) compensatory up-regulation
of redundant receptor tyrosine kinases (RTKs) that signal
through common effectors (pAKT is one such effector).
Benavente et al. [39] have shown constitutive activation of
MET and ErbB3 RTKs in cetuximab- or erlotinib-resistant head
and neck and lung cancer cell lines. Seiwert et al. [40]
demonstrated a greater-than-additive inhibition of cell growth
by combining a MET inhibitor with erlotinib (small-molecule
tyrosine kinase EGFR inhibitor) and synergy was mediated
via ErbB3/AKT signaling. (iii) Ligand-independent signaling
(i.e. EGFRvIII): EGFRvIII is a mutant receptor with an in-
frame deletion of the extracellular domain that renders the
receptor constitutively active despite its inability to bind EGF.
EGFRvIII expression was detected in 42% of HNSCC where
EGFRvIII was always found in conjunction with wild-type
EGFR [41]. HNSCC cells expressing EGFRvIII showed
increased proliferation in vitro and increased tumor volumes
in vivo compared with vector-transfected controls. EGFRvIII-
transfected HNSCC cells showed decreased apoptosis in
response to cisplatin and decreased growth inhibition following
treatment with cetuximab compared with control cells. (iv)
Transcriptional regulatory mechanisms that control EGFR
expression: single-nucleotide polymorphisms (SNPs) in EGFR
promoter region [i.e. GC (EGFR*1)] or common CA
dinucleotide repeat in intron 1 of EGFR affects EGFR mRNA
levels. Higher promoter activity and stronger mRNA expression
have been observed in the non-GC-containing haplotype and
this haplotype may be associated with greater sensitivity to
gefitinib. Shorter number of CA dinucleotide repeats in intron
1 of EGFR was associated with greater in vitro sensitivity to
erlotinib in 14 head and neck cancer cell lines [42]. (v)
Inhibition of the ubiquitin-mediated degradation of EGFR: the
chromosome 11q13 region is frequently amplified in HNSCC
(36%) and results in an increased expression of cortactin [43,
44]. Cortactin acts as an important regulator of the actin
cytoskeleton and mediates the invasive potential of tumor cells
[45]. Cortactin also participates in receptor-mediated
endocytosis and its overexpression inhibits the ubiquitin-
mediated degradation of EGFR, resulting in a sustained ligand-
induced EGFR activity [45].
Chung et al. [46] have shown that a matrix-assisted laser
desorption/ionization mass spectrometry (MS) profile in serum
or plasma can predict HNSCC survival after treatment with
EGFR inhibitors (EGFRI).
Using both the tumor and the skin specimens from EORTC
24061, the predictive value of ErbB signaling on the clinical
outcome of patients with HNSCC treated with a TPF induction
regimen combined with cetuximab in one of the treatment
arms will be tested. The tumor specimens from EORTC 22071-
24071 offer a valuable opportunity to probe the molecular profile
of patients with HNSCC who have all received panitumumab
in their treatment. A gene expression classifier before and after
administration of a single panitumumab dose will be correlated
with PET response. These studies offer a unique opportunity
to identify gene expression changes predictive of response to
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EGFR-targeted therapy. If activation of specific pathways is
associated with resistance, then targeting these pathways will
reverse resistance to EGFR-targeted therapies.
prognostic molecular signatures using genomic
and proteomic profiling
Several research groups have attempted to classify patients with
HNSCC in terms of prognosis using genomic and proteomic
approaches. The most commonly used genomic platforms are
DNA microarrays. This technology has been very effective in
defining prognostic tumor subsets in breast cancer and
lymphomas. A major limitation of its applicability in clinical
trial specimens had been the requirement for frozen tissue
material. Recently, a successful technology for extraction of
RNA from FFPE tissues has been developed. Chung et al. [4],
using complementary DNA (cDNA) microarray technology in
60 fresh frozen HNSCC samples, categorized these tumors
into the following four distinct subtypes with statistically
significant differences in recurrence-free survival: a subtype with
a possible EGFR pathway signature, a mesenchymal-enriched
subtype, a normal-epithelium-like subtype, and a subtype with
high levels of antioxidant enzymes. This signature was validated
in an independent cohort of 40 patients with HNSCC and the
RNA used was extracted from FFPE tumors [47]. Therefore,
global gene expression analysis is feasible using formalin-fixed
tissue. As discussed previously, cDNA microarray technology
will be used to determine the gene expression signature
predictive for response to panitumumab in the postoperative
EORTC 22071-24071 clinical trial.
To carry out comprehensive analysis of genomic
abnormalities in HNSCC, various platforms are available such
as whole-genome array comparative genomic hybridization
(CGH) analysis, structural variation analysis/SNP array
screening, and chromosome- or gene-specific CGH arrays.
Gibcus et al. [43, 48] reported on the identification of several
HNSCC-specific abnormalities, with chromosome 11q13
amplification as the most common. Structural analysis of the
11q13 amplicon combined with expression analysis of the genes
located in the amplicon revealed that cyclin D1, cortactin,
and fas-associated protein death domain are interesting
candidate genes to mediate resistance to chemoradiation
treatment in HNSCC [49]. Therefore, in parallel, gene
expression signature confined to regions with chromosomal
abnormalities will be tested as predictors for response to
panitumumab in the postoperative EORTC 22071-24071
clinical trial.
The field of biomarker discovery has been enriched with the
microRNA microarray technology. The widespread use of
microRNA microarrays has enabled the identification of
a number of microRNAs as potential biomarkers for cancer in
both formalin-fixed tissue and blood [50]. Many microRNAs
function as oncogenes, tumor suppressors, or modulators of
cancer stem cells and metastasis. Studies have not only
identified microRNA biomarkers but also found their target
genes. MicroRNAs have also been implicated in resistance to
EGFR-targeted therapies [51].
In terms of proteomics, the most commonly used platforms
include tissue microarrays (TMAs), MS-based assay, and
protein arrays. TMA technology has emerged as a very useful
tool in facilitating biomarker validation; it is a method used to
analyze hundreds (or even thousands) of tissue specimens on
a single TMA slide. The most widely used end application for
TMA is IHC, although the technique can be coupled with other
molecular biology methods including ISH or in situ PCR.
Essentially, a TMA is made up of individual cylindrical ‘cores’
taken from representative areas of each sample in a cohort.
These cores are then arrayed in an orderly grid into a recipient
paraffin block. Subsequent tissue sections are then made of
this recipient block and processed identically to traditional
whole-section slides. The advantages of TMA over individual
whole-slide sections are several. First, all specimens are treated
to identical conditions throughout the IHC process. In a TMA,
all spots are being incubated simultaneously, thus greatly
reducing variability that might obscure true findings. The
second advantage is the practicality of this approach due to the
utilization of FFPE tissues. Last but not least, another advantage
of TMA is cost and time savings. TMAs have been used to
validate immunohistochemical expression profiles of proteins
that have been indicated as predictors for laryngeal carcinoma
[52, 53]. Using AQUA protein analysis on TMAs composed
of annotated HNSCC cohorts, Psyrri et al. have identified
several prognostic biomarkers as well as biomarkers that
distinguish HPV-positive versus HPV-negative HNSCCs [34,
54–57]. TMAs will be constructed from tissue specimens of
ongoing EORTC clinical trials and will be used for biomarker
validation. MS and protein arrays require frozen tissues and
will be more widely used in the future.
molecular signatures: predictors of toxicities
In recent years, the data imply a genetic basis for a susceptibility
to the development of radiation injury after
(chemo)radiotherapy [52, 53, 58]. A recent study [59]
examined whether patients with severe radiation-induced
sequelae (RIS) both show a low capacity of radiation-induced
CD8 lymphocyte apoptosis (RILA) in vitro and bear certain
SNPs located in candidate genes associated with the response of
cells to radiation. DNA was extracted from blood samples
obtained from 399 patients enrolled in the Swiss prospective
study evaluating the predictive effect of in vitro RILA and RIS.
SNPs in the ATM, SOD2, XRCC1, XRCC3, TGFB1, and RAD21
genes were screened in patients who experienced severe RIS
(group A, n = 16) and control subjects who did not manifest
RIS (group B, n = 18). Overall, 13 and 21 patients were found
to possess a total of less then four and four or more SNPs,
respectively, in the candidate genes. The median (range) RILA
in group A was 9.4% and 94% of the patients (15 of 16) had
four or more SNPs. In group B, median (range) RILA was
25.7% and 33% of patients (6 of 18) had four or more SNPs
(P < 0.001). These findings imply that patients with severe RIS
bear four or more SNPs in candidate genes and display low
RILA in vitro. Mahmut Ozsahin will attempt to validate these
findings in the EORTC 22071-24071 study. This study has
been selected to receive financial support from the EORTC. In
the same study, SNPs in candidate genes will also be screened,
and this study will also be financed by the Swiss National
Funds.
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strategies within EORTC to facilitate TR
The EORTC Translational Research Advisory Committee
(TRAC) will promote TR with the following mechanisms:
(i) availability of large numbers of clinical specimens from
clinical trials, (ii) team expertise, and (iii) funding through
EORTC.
tissue banking
EORTC is developing adopted standardized protocols for
specimen collection, storage, and processing. Kits used with
that contain the required materials and detailed instructions.
The aim of the EORTC tissue bank is to provide qualified
researchers with clinically annotated tissue specimens.
The specimens are sent to the central repository,
de-identified of personal information coded with the study
and case number, and stored. Samples are reviewed by the
pathologist to ensure that tumor tissue is included in the
specimen. Collected material includes unstained slides, tissue
blocks, frozen tissue, and fluids such as plasma. These
specimens become available to the researchers after submission
and endorsement of proposals to the EORTC TRAC. These
proposals are reviewed by the EORTC for scientific merit,
sample availability, and statistical validity.
EORTC NOCI group
EORTC NOCI consists of 23 high-level cancer centers highly
involved in EORTC activities, which have signed a consortium
agreement to conduct TR. NOCI institutions have been selected
for their earlier accomplishments and successful work in
various EORTC groups. The principal goal of NOCI is
contacting the most challenging research studies in the field of
phase II trials of novel compounds and bridging the gap from
laboratory to the clinic by carrying out TR studies. The work
within NOCI group involves also mutual collaboration of all
EORTC groups covering cancer sites and oncology branches.
Having organized the network NOCI, EORTC proved once
more the organization’s efforts to carry out top-quality clinical
research and its commitment to translational clinical research
in oncology.
The NOCI call at EORTC Group Annual Meetings (EGAM)
was conceived to promote EORTC scientific strategy and NOCI
projects. The EORTC Board has allocated support for this
initiative to promote clinico-genomic trials that cannot be
adequately supported by the pharmaceutical industry. In 2009,
eight proposals representing nine EORTC groups were
presented at a session dedicated to this call for NOCI projects at
the 2009 EGAM. The criteria used to evaluate the proposals
were as follows: originality, innovation and adherence to
EORTC scientific strategy, the potential impact of the study on
clinical practice, the strength of the TR component, the
suitability of the methodology, the feasibility, and statistical
robustness. Three proposals were selected to receive grants
including one proposal from the EORTC-ROG and the
EORTC-HNCG: ‘‘Radiation-induced normal tissue toxicities in
patients to be included in the randomized phase III trial on
postoperative chemoradiation in combination with anti-EGFR
antibody versus postoperative chemoradiation alone in head
and neck squamous-cell carcinomas with high risk of
locoregional recurrence (Protocol 22071-24071)’’ presented by
Mahmut Ozsahin.
collaboration between individual groups and the
Translational Research Division
The Translational Research Division (TRD) consists of basic
scientists focusing on cancer research. Personalized cancer
care requires treatment tailoring depending on the molecular
profile of the individual tumor and a close collaboration
between scientists and clinicians becomes more urgent. The
division includes the EORTC Pharmacology and Molecular
Mechanisms, the PathoBiology Group, and the functional
imaging group during the EGAM. This collaboration aims to
identify basic science discoveries ‘ripe’ for translation and
accelerate prioritized opportunities.
funding mechanism
The scientific merits of proposals are evaluated based on the
scientific, statistical, and financial information provided in the
TR project application form to justify the requested use of
tissue bank specimens and funding (Figure 1). Proposals that
seek to validate biomarkers and have applicability to future
clinical trials are deemed as high priority. Hypothesis
generating projects that bring innovative research and appear
promising are also considered.
Submission of the TR project to
HNCG  committee and the
EORTC Headquarters for merit, 
sample availability, statistical 
considerations, and feasibility of 
the project 
Submission and approval by PRC 
Endorsement by the Translational 
Research Advisory Committee 
(TRAC)
Continued statistical and bionformatics
support and collaboration with EORTC 
Headquarters for data analysis
Figure 1. Schema for the translational research program application
review. EORTC, European Organisation for Research and Treatment of
Cancer; HNCG, Head and Neck Cancer Group; PRC, project review
committee; TR, translational research.
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bioinformatics and statistical support
EORTC will provide research support in experimental design,
bioinformatics, and statistics through the statistics group at
EORTC Headquarters. Projects using genomic and proteomic
platforms require strong support in bioinformatics.
conclusion/future perspectives
The substantial progress in head and neck cancer research in
research laboratories has not yet resulted in the translation
of the findings to the clinic. Advances in molecular biology
such as the ‘omic’ approaches have demonstrated distinct
prognostic head and neck cancer patient subsets beyond those
defined by traditional clinical–pathological factors. Validation
of these biomarkers in large prospective clinical trials is
required before their clinical implementation. The strategy of
translating these research findings into population-based,
multi-institutional EORTC clinical trials for subsequent clinical
application remains a challenge. The head and neck cancer
TR subcommittee at the EORTC is committed to accelerate the
translation of prioritized basic science discoveries. The
construction of a tissue/serum bank of clinically annotated
samples combined with the coordinated efforts of the EORTC-
HNCG and the TRD aims to accelerate TR and personalize
head and neck cancer management.
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